ライフサイエンスコーパス: arrhythmic

1 ould be classified as cardiovascular but not arrhythmic.

2 onal AP propagation dispersion, which is pro-arrhythmic.

3 Both arrhythmic (1/f-type) and rhythmic (band) activities wer

4 207 of which (3.7%; 95% CI, 3.3%-4.2%) were arrhythmic (161 arrhythmias, 30 cardiac device implantat

5 These include impaired and arrhythmic action potential burst discharge associated w

6 prolonged cardiac repolarization and abolish arrhythmic activities.

7 LQT3 sodium channel variants and suppressing arrhythmic activity across multiple genetic and pharmaco

8 Cardiac pathologies associated with arrhythmic activity are often accompanied by inflammatio

9 Our results show that the main source of arrhythmic activity was localized to the higher-order th

10 This arrhythmic activity was localized to the higher-order th

11 f action potential duration with evidence of arrhythmic activity, parameters which could not have bee

12 nalogue of a benzoxathiin that has high anti-arrhythmic activity.

13 ted epicardial action potential notch but no arrhythmic activity.

14 It is the first 'anti-arrhythmic' adaptive response in the setting of AF and a

15 Dofetilide is one of the only anti-arrhythmic agents approved for atrial fibrillation (AF)

16 The actions of multi-channel class III anti-arrhythmic agents vernakalant and amiodarone were introd

17 r AP morphology are the primary cause of pro-arrhythmic alternans.

18 t hemodialysis enrolled in the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Di

19 endpoint of cardiovascular death, and major arrhythmic and major heart failure events.

20 idence of phenotypic progression and adverse arrhythmic and nonarrhythmic events over long-term follo

21 d natural history studies of LMNA-associated arrhythmic and nonarrhythmic outcomes are limited, and t

22 This study sought to describe the arrhythmic and nonarrhythmic outcomes of LMNA mutation c

23 of 30-day SAEs, including death and cardiac (arrhythmic and nonarrhythmic) and noncardiac events.

24 partially sustains homeostasis in otherwise arrhythmic and prematurely aging animals.

25 ing rescued spatial memory deficits in these arrhythmic animals.

26 cle in the livers of (1) wild-type mice, (2) arrhythmic Arntl knockout mice, (3) mice fed at regular

27 release, regarding the tissue origin of the arrhythmic beats that initiate ventricular tachycardia,

28 Period1/2/3 triple mutant mice, resulting in arrhythmic behavior in constant conditions.

29 imulations of the heart in understanding the arrhythmic behavior in novel therapies for HF.

30 splayed profound autonomic dysregulation and arrhythmic behavior in vivo.

31 or Cre-Ctl hearts exhibited a proclivity for arrhythmic behavior, ranging from frequent ectopy to pac

32 Using arrhythmic Bmal1-null mice, we generated animals with re

33 Overall arrhythmic burden at study inclusion was 56%.

34 d with neurohormonal activation, ventricular arrhythmic burden, and systolic/diastolic dysfunction (a

35 with a neurohormonal activation, ventricular arrhythmic burden, and worse prognosis.

36 ies depending on multiple factors, including arrhythmic burden.

37 (+) channel deficiency, which contributed to arrhythmic burst discharge.

38 SK blockade partially suppressed the arrhythmic burst pacing pattern of intact NCX KO SAN tis

39 ly normalized SR Ca(2+) handling, attenuated arrhythmic Ca(2+) activities, and alleviated atrial fibr

40 cardiomyocytes had a significant increase in arrhythmic calcium traces compared to isogenic controls.

41 te sensitivity to alcohol, leading to sudden arrhythmic cardiac death in the second decade of life.

42 Arrhythmic causes were found in 14% while no cause was i

43 However, the arrhythmic CCA1 overexpression line (CCA1-OX) displayed

44 cardiographic, structural, histological, and arrhythmic characteristics.

45 remains synchronous and rhythmic even in an arrhythmic clock mutant host.

46 phenotypes of PhLHY in Arabidopsis caused an arrhythmic clock phenotype, which resembles those of LHY

47 The temporal occurrence of arrhythmic complications after alcohol septal ablation (

48 The outcome event was an arrhythmic composite end point of sudden cardiac death o

49 vomilenine can be transformed into the anti-arrhythmic compound ajmaline, or alternatively, can isom

50 our adjudicated primary outcome was serious arrhythmic conditions (arrhythmias, interventions for ar

51 with cardiomyopathy and high risk inherited arrhythmic conditions and secondary prevention in surviv

52 are influenced by CSQ2 and are disrupted in arrhythmic conditions.

53 is effective in potentially eliminating the arrhythmic consequences of this genetic disease.

54 iac-specific gene expression and resulted in arrhythmic contracting cardiomyocytes in vitro.

55 vation was augmented by specific patterns of arrhythmic correspondence.

56 Considerable research has described the arrhythmic course of arrhythmogenic right ventricular dy

57 endent bioluminescence rhythms in previously arrhythmic Cry1/2-deficient SCN, with periods appropriat

58 Primary outcome parameter was arrhythmic death (AD) or resuscitated cardiac arrest (RC

59 istics could identify autopsy-defined sudden arrhythmic death (SAD) among presumed SCDs.

60 Resuscitated cardiac arrest and arrhythmic death caused by ventricular tachyarrhythmias

61 on that are known to increase risk of sudden arrhythmic death in humans.

62 xpression of the microRNA resulted in sudden arrhythmic death of most of the treated pigs.

63 sus testing by use of a composite outcome of arrhythmic death or failed appropriate shock (ie, a shoc

64 The primary outcome of arrhythmic death or failed appropriate shock occurred in

65 The primary endpoint was SCA defined as arrhythmic death or ICD discharge for ventricular fibril

66 ow-up, there were 33 sudden cardiac arrests (arrhythmic death or implantable cardiac defibrillator di

67 There was one arrhythmic death related to asystole in a single ventric

68 ary artery disease (40%), followed by sudden arrhythmic death syndrome (14%).

69 st common SCA-related conditions were sudden arrhythmic death syndrome (31%), coronary artery disease

70 Sudden arrhythmic death syndrome (SADS) describes a sudden deat

71 en identified in families affected by sudden arrhythmic death syndrome (SADS) remains unclear.

72 Sudden arrhythmic death syndrome (SADS) was the most prevalent

73 ric patients with a family history of sudden arrhythmic death syndrome assessed from 2010 to 2013 in

74 Sudden arrhythmic death syndrome defines a sudden unexpected an

75 Proportion of SCD related to sudden arrhythmic death syndrome increased during the study per

76 Proportion of SCD related to sudden arrhythmic death syndrome increased over the study perio

77 ardiac death with a normal heart (ie, sudden arrhythmic death syndrome).

78 cy virus (HIV+) have greater risk for sudden arrhythmic death than HIV-uninfected (HIV-) individuals.

79 factors that distinguish patients at risk of arrhythmic death versus heart failure could better targe

80 that mdx mice, which lack dystrophin, had an arrhythmic death when stimulated with isoproterenol; the

81 However, "arrhythmic death" has caught practically all the attenti

82 therapies by the device and none suffered an arrhythmic death.

83 ut does not improve shock efficacy or reduce arrhythmic death.

84 sk factor for lethal cardiac arrhythmias and arrhythmic death.

85 diac death, resuscitated cardiac arrest, and arrhythmic death.

86 nction might improve risk stratification for arrhythmic death.

87 ion to heart failure deterioration or sudden arrhythmic death.

88 myocardial ischemia is a precursor of sudden arrhythmic death.

89 antable cardioverter-defibrillator efficacy (arrhythmic deaths and ineffective shocks), and composite

90 No arrhythmic deaths occurred during the follow-up.

91 ic; it is unclear what proportion represents arrhythmic deaths.

92 Voltage mapping revealed disorganized and arrhythmic depolarizations within the NCX KO SAN that fa

93 type; WT) and from a genetic murine model of arrhythmic disease (catecholaminergic ventricular tachyc

94 tissues produce a disproportionate burden of arrhythmic disease and are major predictors of mortality

95 ytes and provide a new platform for studying arrhythmic disorders leading to sudden cardiac death.

96 scular diseases, including cardiomyopathies, arrhythmic disorders, vascular disorders, and lipid diso

97 assifier that stratifies drugs into safe and arrhythmic domains for any combinations of these two cur

98 Our study of behaviorally arrhythmic Drosophila circadian period mutants identifie

99 ors for simulation-guided approaches to anti-arrhythmic drug development and patient-specific therape

100 dial oxygen consumption, until adequate anti-arrhythmic drug levels are reached to safely perform cat

101 Amiodarone is an anti-arrhythmic drug that was approved by the US Food and Dru

102 (Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial [C

103 Anti-arrhythmic drug therapy is a frontline treatment for atr

104 be a predictor of the effectiveness of anti-arrhythmic drug therapy.

105 otch1 heterozygosity and low oxygen- or anti-arrhythmic drug-induced gestational hypoxia, resulting i

106 and patients without use of class I/III anti-arrhythmic drugs or digoxin.

107 armacological agents (such as Class III anti-arrhythmic drugs).

108 ulation by the acute action of selected anti-arrhythmic drugs.

109 ily oscillations that are believed to become arrhythmic during aging.

110 ty of the model to reproduce potentially pro-arrhythmic dynamics under perturbed conditions, pertaini

111 BMAL1 C terminus including the TAD exhibited arrhythmic eclosion behavior.

112 of IKr and IKur produced a synergistic anti-arrhythmic effect in both forms of SQT3.

113 Whether these species exert anti-arrhythmic effects in the acute phase of myocardial isch

114 contradictory results on both pro- and anti-arrhythmic effects of blocking IKur.

115 reduces sympathetic activity and exerts anti-arrhythmic effects.

116 icular assist device implant and a secondary arrhythmic end point of sudden cardiac death or appropri

117 he primary end point, and 88 experienced the arrhythmic end point.

118 ratio, 1.82 [95% CI, 1.20-3.06]) risk of the arrhythmic end point.

119 n present with syncope or a life-threatening arrhythmic episode.

120 No arrhythmic event occurred during class 1A AAD therapy in

121 s advances, we may have new tools to predict arrhythmic event rates in gene carriers.

122 studies to document regional denervation for arrhythmic event risk assessment.

123 ividuals had experienced a potentially fatal arrhythmic event with a median age of onset of 7 years (

124 infarction (p < 0.05) and preceding a tachy-arrhythmic event.

125 was to determine whether mexiletine prevents arrhythmic events (arrhythmic syncope, aborted cardiac a

126 and QRS duration were greater in those with arrhythmic events (both P<0.001) and this was consistent

127 +/- 0.03; p = 0.027), and the annual rate of arrhythmic events (from 10.3% to 0.7%; p = 0.0097).

128 and reduced the percentage of patients with arrhythmic events (from 22% to 3%; p = 0.031), the mean

129 p, only QRSp was an independent predictor of arrhythmic events (hazard ratio, 2.1; P<0.001).

130 Q reduces the occurrence of life-threatening arrhythmic events (LAE) (cardiac arrest or sudden cardia

131 e of ARVC and occurrence of life-threatening arrhythmic events (LAE) and cardiovascular mortality; id

132 ought to define the risk of life-threatening arrhythmic events (LAE), identify predictors of such eve

133 of 2.3 (95% CI: 0.63-8.66; p=0.2) for major arrhythmic events (sustained VAs, sudden cardiac death,

134 ppear to be associated with a higher risk of arrhythmic events after operation.

135 ascular events, and accounted for a third of arrhythmic events after the procedure.

136 determine the impact on therapy changes and arrhythmic events after the procedure.

137 y identify asymptomatic patients at risk for arrhythmic events and could be helpful in investigating

138 gical cryoablation does not seem to increase arrhythmic events and may be protective.

139 patients evaluating the association between arrhythmic events and predictive tests (baroreflex sensi

140 tonomic innervation of the heart may trigger arrhythmic events and stellectomy is a treatment option

141 Nevertheless, arrhythmic events and sudden cardiac death are not negli

142 d with the PMCA1(loxP/loxP) hearts, and such arrhythmic events became more severe under Ca(2+) overlo

143 All arrhythmic events but one were asymptomatic and led to a

144 ic events per patient and the annual rate of arrhythmic events during observation periods of equal du

145 Arrhythmic events in asymptomatic Brugada syndrome patie

146 (QRSp) in high-resolution ECGs would predict arrhythmic events in implantable cardioverter-defibrilla

147 caused a major reduction of life-threatening arrhythmic events in LQT3 patients, thus representing an

148 des novel insights into risk of breakthrough arrhythmic events in LQTS, particularly LQT2.

149 d risk stratification tests as predictors of arrhythmic events in patients with nonischemic dilated c

150 ection fraction for the prediction of future arrhythmic events in patients with systolic dysfunction

151 ghts the importance of an early diagnosis of arrhythmic events in such patients to implement the appr

152 time of 74.3+/-57.3 months (median 57.3), 25 arrhythmic events occurred (16 in the inducible group an

153 Arrhythmic events occurred in only 2 cardiac arrest surv

154 mean follow-up time of 73.2+/-58.9 months, 9 arrhythmic events occurred, accounting for an annual inc

155 om 22% to 3%; p = 0.031), the mean number of arrhythmic events per patient (from 0.43 +/- 0.17 to 0.0

156 acy of mexiletine by comparing the number of arrhythmic events per patient and the annual rate of arr

157 tes with stria pattern experienced malignant arrhythmic events such as appropriate implantable cardia

158 bilize the action potential and suppress pro-arrhythmic events than the rapid delayed rectifier.

159 a(2+) uptake by PLN ablation can prevent the arrhythmic events triggered by SR Ca(2+) leak due to CaM

160 The primary end point of arrhythmic events was defined as appropriate ICD therapy

161 r Kaplan-Meier estimates of the incidence of arrhythmic events were 7% among patients who underwent a

162 r Kaplan-Meier estimates of the incidence of arrhythmic events were 7% among patients who underwent a

163 Ventricular arrhythmic events were identified among 176 patients wit

164 xperienced >/=1 defined breakthrough cardiac arrhythmic events with 5- and 10-year event rates of 4%

165 ysis revealed that a QRSp >/=2.25 identified arrhythmic events with greater sensitivity (100% versus

166 ealth-sponsored PAREPET trial (Prediction of Arrhythmic Events with Positron Emission Tomography).

167 with increased age-dependent risk for major arrhythmic events, and paradoxical responses to beta-adr

168 e of cardiovascular death, heart failure, or arrhythmic events, for patients with or without TTNtv (h

169 HRT is a powerful predictor of both CD and arrhythmic events, particularly in postacute myocardial

170 5% CI, 2.2-3.3) for total mortality, CD, and arrhythmic events, respectively.

171 of 24 (15-43) months, 20 (20%) patients had arrhythmic events.

172 nction is a strong, independent predictor of arrhythmic events.

173 s) increased the predictive power for CD and arrhythmic events.

174 isting clinical metrics in predicting future arrhythmic events.

175 ated with worsening heart failure as well as arrhythmic events.

176 ing to false detection of atrial/ventricular arrhythmic events.

177 methods to identify and locate the origin of arrhythmic excitation.

178 g sic-1 mutant both exhibit low-amplitude or arrhythmic expression of core circadian clock genes unde

179 nt successful radiofrequency ablation of the arrhythmic focus without ventricular tachycardia recurre

180 ARNTL) of select regulators were reduced and arrhythmic following treatment.

181 gene expression are abolished in a circadian arrhythmic frq(ko) mutant.

182 titutive gsn expression resulted in high and arrhythmic glycogen levels, and deletion of gpn abolishe

183 erential gene expression in entrained versus arrhythmic hamsters in the suprachiasmatic nucleus (SCN)

184 ory persisted for at least 3 weeks after the arrhythmic hamsters were switched back to ad libitum fee

185 samples (n=37 and 46, one set with a greater arrhythmic history) were selected to generate pseudo-tim

186 a functional effect in utero that may be pro-arrhythmic in the developing fetus.

187 a functional effect in utero that may be pro-arrhythmic in the developing foetus.

188 ce of core circadian clock genes also became arrhythmic in the rNAD-ME1 line, suggesting that perturb

189 : 32 cm/s, PP1: 41 cm/s, p < 0.05) and lower arrhythmic inducibility (PP3: 71%, PP1: 35%, p < 0.05) t

190 us-9-induced overexpression of SN attenuated arrhythmic induction during stress testing with isoprote

191 that link loss of sodium channel function to arrhythmic instability remain unresolved.

192 mic nervous system is pro-arrhythmic or anti-arrhythmic is multifaceted and varies for different type

193 cking Bmal1 systemically had exacerbated and arrhythmic ISG/Irf7 expression after IMQ.

194 matched cohort of patients treated with anti-arrhythmic medications only in the Outcomes Registry for

195 sly calcifying tendons in young CLOCKDelta19 arrhythmic mice and aged wild-type mice.

196 Arrhythmic mitral valve prolapse (MVP) is characterized

197 u-band oscillations, whereas pulse trains of arrhythmic MNS do not.

198 ernating hemiplegia of childhood, as cardiac arrhythmic morbidity and mortality are potentially preve

199 o heart failure-related mortality but not to arrhythmic mortality.

200 onsidered benign but recent suggestion of an arrhythmic MVP (AMVP) form remains incompletely defined

201 l challenge is how to identify patients with arrhythmic MVP (which imaging technique and in which pat

202 ratification, and treatment of the so-called arrhythmic MVP are unknown.

203 x (27 female patients; median age: 44 years) arrhythmic MVP patients with LV late gadolinium enhancem

204 annulus disjunction is a constant feature of arrhythmic MVP with LV fibrosis.

205 es in sudden death victims and patients with arrhythmic MVP.

206 by which the autonomic nervous system is pro-arrhythmic or anti-arrhythmic is multifaceted and varies

207 ythms: pdf(01) (pdf-null) animals are mostly arrhythmic or short period in constant darkness and have

208 ng-state power fluctuations of broadband and arrhythmic, or scale-free, macaque electrocorticography

209 The clinical profile and arrhythmic outcome of competitive athletes with isolated

210 d subjects as low risk (0.4% risk for 30-day arrhythmic outcome), medium risk (8.7% risk), and high r

211 Overall, 91.7% of arrhythmic outcomes among medium- and high-risk patients

212 One-half of arrhythmic outcomes were identified within 2 hours of ED

213 sensitivity) were significant predictors of arrhythmic outcomes.

214 ier analysis to describe the time to serious arrhythmic outcomes.

215 , GLP-1 secretion was markedly increased but arrhythmic over the 24-h day, whereas levels of the othe

216 plore the use of simulations to improve anti-arrhythmic pacing and defibrillation interventions; to p

217 ndling, to determine the underlying cellular arrhythmic pathogenesis.

218 t hyperactivation of SK channels, leading to arrhythmic pauses alternating with bursts of pacing.

219 get of PDF, we rescued per in PDF neurons of arrhythmic per(0)(1) mutants.

220 13.5, the anlagen of the SCN expresses high, arrhythmic PER2.

221 p for analysis, mapping and detection of pro-arrhythmic phenomena in silico, in cellulo, animal model

222 l locomotor activity and did not enhance the arrhythmic phenotype caused by the Pdf receptor (Pdfr) m

223 1);Pdf(01) double mutants exhibited a severe arrhythmic phenotype compared to Pdf-null mutants (Pdf(0

224 ation led to bradycardia in zebrafish and an arrhythmic phenotype in a subset of the analyzed zebrafi

225 The arrhythmic phenotype of cardiac-Sirt1-deficient mice rec

226 duced affinity for BMAL1/CLOCK and causes an arrhythmic phenotype.

227 reas its inhibitor KN93 or AIP abolished the arrhythmic phenotype.

228 ), although isolated reports have identified arrhythmic phenotypes among heterozygotes.

229 the PDGF signalling pathway ameliorated the arrhythmic phenotypes of mutant iPSC-CMs in vitro.

230 g to myocardial destruction, remodelling and arrhythmic predisposition remain poorly understood.

231 A deeper understanding of the underlying arrhythmic principles is mandatory if we are to improve

232 important factor in determining whether pro-arrhythmic release patterns develop.

233 onal factor contributing to the differential arrhythmic risk among patients with LQT1 carrying the sa

234 alysis program in defining breakthrough LQTS arrhythmic risk beyond the QTc value.

235 Mild hypertrophy but increased arrhythmic risk characterizes the stereotypic phenotype

236 that targeted regulation of Cav1 may reduce arrhythmic risk in cardiac diseases associated with reni

237 region was the primary mechanism increasing arrhythmic risk in transmural versus subendocardial isch

238 tant parameters to consider when determining arrhythmic risk include electric instability, including

239 ics of DCM and how specific mutations affect arrhythmic risk is also rapidly increasing.

240 Determination of ventricular arrhythmic risk is crucial for guiding management of car

241 This arrhythmic risk signature was able to predict T2D in 699

242 ing, and cardiac magnetic resonance enhances arrhythmic risk stratification beyond ejection fraction

243 ck, may identify MVP patients who would need arrhythmic risk stratification.

244 was assessed, and the impact of genotype on arrhythmic risk was evaluated using Cox regression model

245 atients with multiple LGE patterns, although arrhythmic risk was higher among patients receiving prim

246 ram is an independent predictor of increased arrhythmic risk, and Tpe changes with heart rate are eve

247 varying degrees of phenotypic expression and arrhythmic risk.

248 s as an unintended side effect also increase arrhythmic risk.

249 roved insight into the inheritance patterns, arrhythmic risks, and molecular mechanisms of CASQ2-CPVT

250 binding kinetics might display divergent pro-arrhythmic risks.

251 ncluding decreased heart rate and irregular, arrhythmic RR (interbeat) intervals, whereas WT mice exh

252 ensitive nature of SK channels could explain arrhythmic SAN pacemaker activity in the atrial-specific

253 ratification to identify patients at risk of arrhythmic SCD is essential for targeting our healthcare

254 MVP is an underestimated cause of arrhythmic SCD, mostly in young adult women.

255 )] restores autonomous circadian activity in arrhythmic SCN-lesioned (SCNX) C3H/HeN mice.

256 Circadian-arrhythmic Siberian hamsters (Phodopus sungorus) exhibit

257 iteria, allows for a direct visualization of arrhythmic spiral re-entry and represents a revolutionar

258 The dual action of JNK2 in CaMKII-dependent arrhythmic SR Ca(2+) leak and a CaMKII-independent uptak

259 itum feeding, locomotor activity resumed its arrhythmic state, but performance on the SA task varied

260 polarization kinetics which results in a pro-arrhythmic state.

261 Patients with refractory arrhythmic storm admitted between January 2005 and March

262 Patients with intractable refractory arrhythmic storm and cardiogenic shock despite optimal m

263 achycardias (VTs; cycle lengths, 230-740 ms, arrhythmic storm n=28) and 2 ventricular fibrillation tr

264 racorporeal life support to treat refractory arrhythmic storm responsible for cardiogenic shock in pa

265 h extracorporeal life support for refractory arrhythmic storm responsible for cardiogenic shock resis

266 thmias during quinidine therapy Conclusions: Arrhythmic storm with recurrent polymorphic VT in patien

267 hospital mortality was 17% for patients with arrhythmic storm.

268 Arrhythmic storms (4-16 events of polymorphic VT deterio

269 These arrhythmic storms were always refractory to conventional

270 Our results suggest that anti-arrhythmic strategies that increase atrial APD without i

271 ns and promotes the progress of current anti-arrhythmic strategies.

272 , treated with dofetilide as an initial anti-arrhythmic strategy for AF, drug discontinuation rates w

273 artial inhibition of IKs as a potential anti-arrhythmic strategy in SQT2.

274 ko) hearts became more susceptible to atrial arrhythmic stress conditions than PMCA1(loxP/loxP) heart

275 approach that could improve the efficacy of arrhythmic substrate ablation in the thick ventricular m

276 f cardiac magnetic resonance for imaging the arrhythmic substrate, both as a research tool and for cl

277 guided by direct pathophysiologic markers of arrhythmic substrate, such as specific left ventricular

278 lation with acetic acid enabled the intended arrhythmic substrate, whether deep or superficial, to be

279 tion similar to humans, to better define the arrhythmic substrate.

280 Arrhythmic sudden cardiac death (SCD) may be caused by v

281 table cardioverter-defibrillator firings and arrhythmic sudden cardiac death) at 5 years of follow-up

282 death occurred in 18 patients (3%; 0.54%/y): arrhythmic sudden death (n=12), progressive heart failur

283 ng events: progressive heart failure (n=17); arrhythmic sudden death (SD) (n=17); and embolic stroke

284 ith LV apical aneurysms are at high risk for arrhythmic sudden death and thromboembolic events.

285 There were no arrhythmic sudden death events among the 217 patients wi

286 or more of its major disease pathways (i.e., arrhythmic sudden death risk; progressive heart failure

287 dentifying high-risk patients susceptible to arrhythmic sudden death with a sensitivity of only 33%,

288 tor to heart failure morbidity or a cause of arrhythmic sudden death; when treated, it is associated

289 fibrillation [AF], and 4% with a history of arrhythmic syncope).

290 ether mexiletine prevents arrhythmic events (arrhythmic syncope, aborted cardiac arrest, or sudden ca

291 y reported harbor genes underlying inherited arrhythmic syndromes and/or cardiomyopathies suggesting

292 Thus, a cohort-specific risk pattern of arrhythmic taxa enables classification and prediction of

293 r changing atrial conduction and age-related arrhythmic tendency.

294 nform safety and efficacy evaluation of anti-arrhythmic therapy in acute myocardial ischemia.

295 The arrhythmic transcription of core circadian genes and dow

296 Despite rapid implementation of anti-arrhythmic treatment and sedation and controlling the tr

297 y provide important insights into novel anti-arrhythmic treatments in heart failure.

298 S, absence of acute coronary syndrome as the arrhythmic trigger, and >/=10 patients included.

299 -ran in rats under a RGB:RG cycle and became arrhythmic under RGB:RGV.

300 eentry at the ischemic border zone explained arrhythmic vulnerability in subendocardial ischemia, esp